CagriSema is Novo Nordisk's bet on the next step after Semaglutide. It pairs semaglutide with Cagrilintide, a long-acting amylin analog, in one weekly injectable. Novo filed for FDA approval in December 2025 and expects a decision in the fourth quarter of this year [1].
Today at the European Association for the Study of Diabetes (EASD) meeting, Novo presented three studies that look past the scale. They measured brain responses to food, fat stored in and around organs, and markers of bone health [1]. This article covers what those studies found and how they fit with the rest of the CagriSema trial record.
Why add amylin
Amylin is a hormone released from the pancreas alongside insulin after meals. It slows stomach emptying and signals fullness to the brain through pathways that overlap only partly with GLP-1. The idea behind CagriSema is that hitting both systems gives more appetite control than either one alone. Cagrilintide is the long-acting amylin piece that makes once-weekly dosing possible. For background on the peptide itself, see our Cagrilintide page.
Study 1: food noise on brain scans
"Food noise" is the popular term for constant, intrusive thoughts about eating. Many people on GLP-1 drugs say it quiets down, but it has been hard to measure.
In a 52-week study of adults with overweight or obesity, researchers used functional MRI to watch how the brain reacted to pictures of tempting, high-calorie food. On CagriSema, responses changed in regions linked to cravings, reward, sensory processing and behavioral control. Participants also reported less food noise, fewer cravings, less hunger and better craving control at both 22 and 52 weeks [1].
Those changes came with a 22.4% reduction in body weight compared with placebo at 52 weeks, reported as the estimated treatment difference [1]. The abstract won a Best Abstract Award at EASD. "This was coupled with reduced energy intake and body weight, showing the association between tackling 'food noise' and successful and sustained weight loss," said Professor Tony Goldstone of Imperial College London [1].
One caution: brain imaging shows association. It does not prove that the brain changes caused the weight loss.
Study 2: fat around the liver and pancreas
Fat stored inside the abdomen and in organs such as the liver and pancreas, called ectopic fat, is closely tied to insulin resistance. An MRI sub-study of the phase 3 REIMAGINE 1 trial looked at adults with early type 2 diabetes. On CagriSema 2.4 mg/2.4 mg, participants had significant reductions in abdominal fat, liver fat and pancreatic fat compared with placebo, alongside 14.3% weight loss at week 40 [1][2].
Study 3: bone markers
Rapid weight loss can come with bone loss, so bone health is a fair question for any drug that produces large weight reductions. A post hoc analysis of the REIMAGINE 2 trial in adults with type 2 diabetes looked at blood markers of bone formation and breakdown. With 14.2% weight loss at week 68, the markers suggested a healthy balance in bone remodeling. The authors described the results as "preliminary reassurance regarding bone changes" [1]. Blood markers are an early signal. Bone density scans and fracture data over longer periods would give a clearer answer.
Where CagriSema stands on weight loss
The EASD studies sit on top of a large trial program with mixed headlines.
- REDEFINE 1, published in 2025, tested CagriSema 2.4 mg/2.4 mg in adults with obesity or overweight. Average weight loss was 20.4% at 68 weeks, compared with 3.0% on placebo [3].
- REDEFINE 4, reported in February 2026, was an open-label head-to-head trial against Tirzepatide 15 mg over 84 weeks in 809 adults. CagriSema produced 23.0% weight loss against 25.5% for tirzepatide using the efficacy estimand, and missed its primary goal of showing it was at least as good [4].
- REIMAGINE 5 and REDEFINE 9, announced at Novo's Capital Markets Day on September 21, tested a lower 1.0 mg/1.0 mg dose. In type 2 diabetes, CagriSema 1.0 mg/1.0 mg beat tirzepatide 5 mg on weight loss at 60 weeks (12.4% vs 9.1%) with similar A1C reduction (1.71 vs 1.67 points). In people with overweight or obesity, the same dose produced 21.0% weight loss against 2.0% on placebo at 68 weeks [5].
Put together, CagriSema at full dose trails the highest tirzepatide dose on weight loss, while lower doses look strong for their size. Novo has also started a phase 3 trial of a high-dose version, CagriSema 2.4 mg/7.2 mg, which uses a higher semaglutide dose [1].
What comes next
The FDA decision on CagriSema for weight management is expected before the end of the year, with a Health Canada decision on a similar timeline [5]. If it is approved, it would be the first weight management drug in the US to combine amylin and GLP-1 activity.
For people comparing options, the EASD data add to the case that weight loss quality matters, along with how much weight comes off. Fat location, bone health and appetite control all show up in how people feel on treatment and whether they stay on it. We will update our Cagrilintide and Semaglutide pages when the FDA rules.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. CagriSema is an investigational product. Talk with a qualified healthcare provider before starting, stopping or changing any treatment.
Sources
- Novo Nordisk. Novo's investigational obesity and diabetes drug CagriSema reduces 'food noise' and shows benefits in organ and bone health: EASD 2026. September 30, 2026.
- Pratley RE, et al. Efficacy of CagriSema on body composition in participants with early type 2 diabetes: REIMAGINE 1. EASD Annual Meeting 2026.
- Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2025.
- Novo Nordisk. CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity; the primary endpoint was not achieved. February 23, 2026.
- Novo Nordisk. Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial. September 2026.